Receptors, Cholecystokinin

• 

  Subject Areas on Research

  • A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. 
  • A whole animal chemical screen approach to identify modifiers of intestinal neutrophilic inflammation. 
  • Alterations in receptors for sensory neuropeptides in human inflammatory bowel disease. 
  • Beneficial effects of cholecystokinin-receptor blockade and inhibition of proteolytic enzyme activity in experimental acute hemorrhagic pancreatitis in mice. Evidence for cholecystokinin as a major factor in the development of acute pancreatitis. 
  • Brain cholecystokinin receptors. Binding characteristics, covalent cross-linking, and evolutionary aspects. 
  • CCK-A- and CCK-B-like receptors in the gallbladder and stomach of the alligator (Alligator mississippiensis). 
  • CCK-X receptors in the endothermic mako shark (Isurus oxyrinchus). 
  • Central and peripheral effects of CCK receptor antagonists on satiety in dogs. 
  • Characterization of cholecystokinin receptors in bullfrog (Rana catesbeiana) brain and pancreas. 
  • Cholecystokinin and its receptors in vertebrates and invertebrates. 
  • Cholecystokinin and neuropeptide Y receptors on single rabbit vagal afferent ganglion neurons: site of prejunctional modulation of visceral sensory neurons. 
  • Control of cholecystokinin receptor dephosphorylation in pancreatic acinar cells. 
  • Differences in receptor binding and stability to enzymatic digestion between CCK-8 and CCK-58. 
  • Differential localization of cholecystokinin-8 binding sites in the rat vs. the guinea pig brain. 
  • Do antagonists of pancreatic cholecystokinin receptors interact with central nervous system cholecystokinin receptors? 
  • Effects of a novel cholecystokinin (CCK) receptor antagonist, MK-329, on gallbladder contraction and gastric emptying in humans. Implications for the physiology of CCK. 
  • Evidence for a common evolutionary origin of brain and pancreas cholecystokinin receptors. 
  • Hunger in humans induced by MK-329, a specific peripheral-type cholecystokinin receptor antagonist. 
  • Integrated actions of cholecystokinin on the gastrointestinal tract: use of the cholecystokinin bioassay. 
  • Intraventricular CCK-8 reduces single meal size in the baboon by interaction with type-A CCK receptors. 
  • Localization of cholecystokinin A and cholecystokinin B/gastrin receptors in the canine upper gastrointestinal tract. 
  • Natural and synthetic CCK-58. Novel reagents for studying cholecystokinin physiology. 
  • Purification, amino acid sequence, synthesis, and receptor selectivity of alligator gastrin. 
  • Receptor binding sites for cholecystokinin, galanin, somatostatin, substance P and vasoactive intestinal polypeptide in sympathetic ganglia. 
  • Regulation of intestinal cholecystokinin and somatostatin mRNA by bombesin in rats. 
  • Regulation of pancreatic endocrine function by cholecystokinin: studies with MK-329, a nonpeptide cholecystokinin receptor antagonist. 
  • Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. 
  • Trigeminal and dorsal root ganglion neurons express CCK receptor binding sites in the rat, rabbit, and monkey: possible site of opiate-CCK analgesic interactions.